Aclaris Therapeutics Stock Forecast

Stock Price Forecast

According to 11 analysts polled by S&P Global, Aclaris Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $10. The average 1-year stock price forecast is 106.61% higher than the current stock price, while the lowest is $4.00 (-17.36%) and the highest is $16 (+230.58%).

Price Target: $10 (+106.61%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$4.00	$10	$10	$16
Change	-17.36%	+106.61%	+106.61%	+230.58%

Analyst Ratings

The average analyst rating for Aclaris Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	6	6	6	7	8	9
Buy	1	1	1	1	1	1
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	9	10	11

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Kate Dellorusso LifeSci Capital	LifeSci Capital	Buy Initiates $13	Buy	Initiates	$13	+168.60%	Jun 1, 2026
Biren Amin Piper Sandler	Piper Sandler	Buy Maintains $11	Buy	Maintains	$11	+127.27%	May 11, 2026
Seamus Fernandez Guggenheim	Guggenheim	Buy Reiterates $12	Buy	Reiterates	$12	+147.93%	May 11, 2026
Ram Selvaraju H.C. Wainwright	H.C. Wainwright	Buy Reiterates $16	Buy	Reiterates	$16	+230.58%	May 11, 2026
Martin Fan Wedbush	Wedbush	Buy Maintains $10	Buy	Maintains	$10	+106.61%	May 8, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

5.71M

from 7.83M

-27.00%

from 7.83M

Revenue Next Year

5.36M

from 5.71M

-6.20%

from 5.71M

EPS This Year

-0.66

from -0.53

EPS Next Year

-0.73

from -0.66

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	6.76M	29.75M	31.25M	18.72M	7.83M	5.71M
Revenue Growth	4.30%	340.05%	5.03%	-40.09%	-58.19%	-27.00%
Gross Profit	-41.77M	-60.02M	-83.00M	-30.32M	-52.10M	542.70K
Gross Margin	-617.73%	-201.74%	-265.60%	-161.99%	-665.77%	9.50%
Operating Income	-65.38M	-85.15M	-114.51M	-52.53M	-74.08M	-91.42M
Net Income	-90.87M	-86.91M	-88.48M	-132.07M	-64.92M	-84.78M
EPS	-	-	-	-	-0.53	-0.66
Free Cash Flow	-28.51M	-39.31M	-37.97M	-59.12M	-30.63M	-77.00M
No. Analysts	-	-	-	-	-	10

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	9.0M
Avg	5.7M
Low	2.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	15.6%
Avg	-27.0%
Low	-74.4%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.66
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-